Successful Meeting with FDA on Phase III Design in NSCLC

® III trial design to evaluate efti in combination with KEYTRUDA (pembrolizumab),MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer • TACTI-004 registrational trial will enrol ~750 patients regardless of PD-L1 expression in order to address the entire 1L NSCLC market eligible for anti-PD-1 therapy SYDNEY, AUSTRALIA – 22 July 2024 – Immutep Limited (ASX: IMM